drugset / Trial / NCT00730717
Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum
Phase 2
Withdrawn
Wright State University
Stanford University · collabWake Forest University Health Sciences · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and efficacy of Humira in the treatment of pyoderma gangrenosum.
Timeline
- Start
- 2009-05
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | — |